1. Home
  2. CVR vs CMMB Comparison

CVR vs CMMB Comparison

Compare CVR & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chicago Rivet & Machine Co.

CVR

Chicago Rivet & Machine Co.

HOLD

Current Price

$14.01

Market Cap

10.4M

Sector

Industrials

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

N/A

Current Price

$1.94

Market Cap

9.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CVR
CMMB
Founded
1920
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.4M
9.1M
IPO Year
1995
2023

Fundamental Metrics

Financial Performance
Metric
CVR
CMMB
Price
$14.01
$1.94
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
3.0K
68.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
0.86%
N/A
EPS Growth
N/A
101.67
EPS
N/A
0.04
Revenue
$26,986,627.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$49.25
Revenue Growth
N/A
N/A
52 Week Low
$8.15
$0.87
52 Week High
$15.00
$3.86

Technical Indicators

Market Signals
Indicator
CVR
CMMB
Relative Strength Index (RSI) 52.06 60.10
Support Level $13.32 $1.48
Resistance Level $14.47 $2.24
Average True Range (ATR) 0.51 0.18
MACD 0.02 0.05
Stochastic Oscillator 43.43 91.91

Price Performance

Historical Comparison
CVR
CMMB

About CVR Chicago Rivet & Machine Co.

Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Share on Social Networks: